Steven N. Perrin
President bei ELEDON PHARMACEUTICALS, INC.
Vermögen: 2 060 $ am 31.03.2024
Profil
Steven N.
Perrin is the founder of Anelixis Therapeutics, Inc. (founded in 2013) where he held the title of President, CEO, Treasurer & Director.
He is currently the Executive Chairman & Chief Scientific Officer at ALS Therapy Development Foundation, Inc. (since 2007) and the President, Chief Scientific Officer & Director at Eledon Pharmaceuticals, Inc. (since 2020).
Previously, he worked at Biogen, Inc. (2001-2006) as an Associate Director-Molecular Profiling, Biogen MA, Inc. as a Scientist, ARIAD Pharmaceuticals, Inc. as a Scientist, Aventis Pharmaceuticals, Inc. as a Scientist, Boston University as an Assistant Professor, and Hoechst Ariad Genomics Center Llc as a Principal.
He received his undergraduate degree from Boston College in 1987 and his doctorate degree from Boston University School of Medicine in 1994.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.05.2023 | 1 000 ( 0,00% ) | 2 060 $ | 31.03.2024 |
Aktive Positionen von Steven N. Perrin
| Unternehmen | Position | Beginn |
|---|---|---|
| ELEDON PHARMACEUTICALS, INC. | President | 14.09.2020 |
ALS Therapy Development Foundation, Inc.
 ALS Therapy Development Foundation, Inc. Pharmaceuticals: MajorHealth Technology ALS Therapy Development Foundation, Inc. develops therapeutic drugs. It provides unmet medical needs. The firm discovers small molecules, protein biologics, gene therapies, and cell-based constructs. The company was founded by James Allen Heywood in 1999 and is headquartered in Cambridge, MA. | Chairman | 01.06.2010 |
Ehemalige bekannte Positionen von Steven N. Perrin
| Unternehmen | Position | Ende |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01.12.2006 |
Anelixis Therapeutics, Inc.
 Anelixis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anelixis Therapeutics, Inc. operates as a clinical stage, privately held biotechnology company. It develops treatments for patients with neurodegenerative disease, people requiring an organ or cell based transplant, as well as people with an autoimmune disease. The company was founded by Steve Perrin in 2015 and is headquartered in Cambridge, MA. | Founder | - |
Hoechst Ariad Genomics Center Llc
 Hoechst Ariad Genomics Center Llc Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Hoechst Ariad Genomics Center Llc is a research center for genomics. The private company is based in Cambridge, MA. Hoechst Ariad Genomics Center was acquired by Hoechst Marion Roussel SA from ARIAD Pharmaceuticals, Inc. on January 04, 2000 for $40 million. | Corporate Officer/Principal | - |
| Boston University | Corporate Officer/Principal | - |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Steven N. Perrin
| Boston College | Undergraduate Degree |
| Boston University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| ELEDON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Hoechst Ariad Genomics Center Llc
Hoechst Ariad Genomics Center Llc Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Hoechst Ariad Genomics Center Llc is a research center for genomics. The private company is based in Cambridge, MA. Hoechst Ariad Genomics Center was acquired by Hoechst Marion Roussel SA from ARIAD Pharmaceuticals, Inc. on January 04, 2000 for $40 million. | Commercial Services |
ALS Therapy Development Foundation, Inc.
ALS Therapy Development Foundation, Inc. Pharmaceuticals: MajorHealth Technology ALS Therapy Development Foundation, Inc. develops therapeutic drugs. It provides unmet medical needs. The firm discovers small molecules, protein biologics, gene therapies, and cell-based constructs. The company was founded by James Allen Heywood in 1999 and is headquartered in Cambridge, MA. | Health Technology |
Anelixis Therapeutics, Inc.
Anelixis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anelixis Therapeutics, Inc. operates as a clinical stage, privately held biotechnology company. It develops treatments for patients with neurodegenerative disease, people requiring an organ or cell based transplant, as well as people with an autoimmune disease. The company was founded by Steve Perrin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
